162 related articles for article (PubMed ID: 29322935)
1. Classifying cancer genome aberrations by their mutually exclusive effects on transcription.
Dayton JB; Piccolo SR
BMC Med Genomics; 2017 Dec; 10(Suppl 4):66. PubMed ID: 29322935
[TBL] [Abstract][Full Text] [Related]
2. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
[TBL] [Abstract][Full Text] [Related]
3. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
[TBL] [Abstract][Full Text] [Related]
4. Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.
Planck M; Edlund K; Botling J; Micke P; Isaksson S; Staaf J
PLoS One; 2013; 8(10):e78614. PubMed ID: 24205279
[TBL] [Abstract][Full Text] [Related]
5. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
[TBL] [Abstract][Full Text] [Related]
7. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
Sintupisut N; Liu PL; Yeang CH
Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
Liu H; Zhang B; Sun Z
Cancer Commun (Lond); 2020 Jan; 40(1):43-59. PubMed ID: 32067422
[TBL] [Abstract][Full Text] [Related]
9. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
10. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
11. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
12. An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.
Lu X; Zhang K; Van Sant C; Coon J; Semizarov D
BMC Med Genomics; 2010 Jun; 3():23. PubMed ID: 20569491
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
Marks JL; McLellan MD; Zakowski MF; Lash AE; Kasai Y; Broderick S; Sarkaria IS; Pham D; Singh B; Miner TL; Fewell GA; Fulton LL; Mardis ER; Wilson RK; Kris MG; Rusch VW; Varmus H; Pao W
PLoS One; 2007 May; 2(5):e426. PubMed ID: 17487277
[TBL] [Abstract][Full Text] [Related]
14. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
[TBL] [Abstract][Full Text] [Related]
15. A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy.
Li Z; Chen S; Feng W; Luo Y; Lai H; Li Q; Xiu B; Li Y; Li Y; Huang S; Zhu X
EBioMedicine; 2020 Dec; 62():103074. PubMed ID: 33161227
[TBL] [Abstract][Full Text] [Related]
16. Genomic aberrations in lung adenocarcinoma in never smokers.
Job B; Bernheim A; Beau-Faller M; Camilleri-Broët S; Girard P; Hofman P; Mazières J; Toujani S; Lacroix L; Laffaire J; Dessen P; Fouret P;
PLoS One; 2010 Dec; 5(12):e15145. PubMed ID: 21151896
[TBL] [Abstract][Full Text] [Related]
17. Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines.
Suzuki A; Makinoshima H; Wakaguri H; Esumi H; Sugano S; Kohno T; Tsuchihara K; Suzuki Y
Nucleic Acids Res; 2014 Dec; 42(22):13557-72. PubMed ID: 25378332
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of small cell lung cancer in a Japanese cohort.
Wakuda K; Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi S; Ono A; Taira T; Naito T; Murakami H; Mori K; Endo M; Nakajima T; Ohde Y; Takahashi T; Yamamoto N
Lung Cancer; 2014 May; 84(2):139-44. PubMed ID: 24657128
[TBL] [Abstract][Full Text] [Related]
19. Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer.
Chao HH; He X; Parker JS; Zhao W; Perou CM
PLoS One; 2012; 7(12):e51719. PubMed ID: 23284754
[TBL] [Abstract][Full Text] [Related]
20. CERNA SEARCH METHOD IDENTIFIED A MET-ACTIVATED SUBGROUP AMONG EGFR DNA AMPLIFIED LUNG ADENOCARCINOMA PATIENTS.
Kabat H; Tunkle L; Lee I
Pac Symp Biocomput; 2017; 22():438-448. PubMed ID: 27896996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
